美迪西作为济民可信的长期合作伙伴，为JMZ-2102和JMZ-2102胶囊提供了从适应症设计、活性成分筛选到系统药效学评价的服务。​双方协同互补，为该药物的高效推进和成功获批临床提供了关键支撑。

作为艾立康药业的合作伙伴，美迪西凭借扎实的药效评价能力和高质量的服务，为ALK2401片提供了临床前药效学研究支持，有力加速了该药物的研发进程。

美迪西作为横琴新创益的战略合作伙伴，为F-02-2-Na提供了符合中美双报标准的药效试验服务，助力其快速获批临床。

美迪西作为领诺医药合作伙伴，依托一站式生物医药临床前研发服务平台，为SLN12140项目提供了体外药效、药代、安评等研发服务，加速了该创新药物的研发进程。

作为Eluciderm的合作伙伴，美迪西有幸为ELU42的快速获批提供了毒理学研究服务，并因此荣获 Eluciderm 颁发的“卓越服务奖”。此次合作是创新药企与CRO合作创新的典范。

Experimental autoimmune encephalomyelitis (EAE) is the most common animal model of multiple sclerosis (MS), a neuroinflammatory and demyelinating disease characterized by multifocal perivascular infiltrates of immune cells. Although EAE is predominantly considered a T helper 1-driven autoimmune disease, mounting evidence suggests that activated dendritic cells (DC), which are the bridge between innate and adaptive immunity, also contribute to its pathogenesis. Sirtuin 6 (SIRT6), a NAD+-dependent deacetylase involved in genome maintenance and in metabolic homeostasis, regulates DC activation, and its pharmacological inhibition could, therefore, play a role in EAE development. The PK study was performed by Medicilon.

Colorectal tumors, in particular, often show dysregulated WNT/β-catenin signalling. G007-LK may be a candidate for use in preclinical trials to determine the efficacy of this drug in preventing growth of WNT dependent tumors. Doses of the tankyrase inhibitor G007-LK shown to be sufficient to inhibit tumor growth are well tolerated by mice within the time frames investigated. Lineage tracing from LGR5+ intestinal stem cells was reduced upon G007-LK treatment, without altering the main morphological characteristics of the intestine. Moreover, mice treated with G007-LK did not experience weight loss, suggesting that the absorptive capacity of the intestine was not negatively impacted. Medicilon Preclinical Research LCC performed the pharmacokinetic studies.

Cetagliptin demonstrates the great potential for treatment with type 2 diabetes patients based on the inhibition of DPP-4, the increase in GLP-1 and insulin, the decrease in glucose, and might be more effective in DPP-4 inhibition than sitagliptin. This study was conducted in a small, selected population of healthy subjects with normoglycaemia. The results suggest that Cetagliptin, at doses ≥50 mg once daily (QD), exhibited minimal accumulation, inhibited plasma DPP-4 activity by >80% over a 24-hour dosing interval, and increased active glucagon-like-1 peptide (GLP-1) levels without producing hypoglycaemia. The active GLP-1 assays were performed by Medicilon Preclinical Research LLC. Generally, Cetagliptin has favourable clinical tolerability and safety.

Heart failure (HF), known as the terminal stage of various cardiovascular diseases, is characterized by poor prognosis and high mortality. JX01 a promising anti-HF drug candidate, showed good pharmacokinetic and safety profiles. JX01 exhibits better cardiomyocyte protective effects than EMPA in vitro. JX01 exhibits lower minimum effective doses than EMPA in vivo. JX01 has good pharmacokinetic properties. Pharmacokinetic studies were commissioned by Medicilon.

上海美迪西生物医药股份有限公司为SG1001提供了关键的药代动力学研究和符合GLP标准的全套安全性评价研究服务，以及美国FDA IND申报资料撰写，为该项目实现中美双报双批提供了坚实保障。